Posted on

Field Trip Psychedelics Inc. Announces Creation of Field Trip Discovery, the Company’s Drug Development Division

TORONTO, April 9, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, today announced the creation of Field Trip Discovery, the company’s newly formed drug development division.

Appointment of Dr. Nathan Bryson, Chief Science Officer

Field Trip Discovery will be led by Dr. Nathan Bryson, Field Trip’s recently hired Chief Science Officer. Dr. Bryson, who holds his PhD in Chemistry and Postdoctoral Associate Degree from Massachusetts Institute of Technology, has three decades of hands-on research and development experience in the biotechnology and pharmaceutical industries where he has overseen innovation, clinical development, regulatory, quality, global supply chain and medical affairs. Prior to joining Field Trip, Dr. Bryson was the Chief Science Officer for Acerus Pharmaceuticals, a Canadian pharmaceutical company with a portfolio of sexual and reproductive health prescription products. Before Acerus, Dr. Bryson previously served as Chief Science Officer at Cynapsus Therapeutics, a pharma-biotech company that was acquired by Sunovion Pharma, and at Cannasat Therapeutics, a pharmaceutical company developing novel cannabinoid therapeutics of THC and CBD.

Appointment of Dieter Weinand and Helen Boudreau to Board of Directors

The Company is also pleased to announce the appointment of Dieter Weinand and Helen Boudreau to the Board of the Directors, who along with Dr. Michael Ehlers, the Company’s Senior Strategy Advisor, will be supporting Dr. Bryson in the strategic direction of Field Trip Discovery.

Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer. He has a demonstrated ability to recognize opportunity, create a vision and strategy, and mobilize organizations behind successful execution.  Mr. Weinand has launched and marketed some of the industry’s most successful products, including Lipitor, Neurontin, Abilify, and Cipro.

Ms. Boudreau joins the Company’s Board of Directors after most recently serving as Chief Operating Officer for the Bill & Melinda Gates Medical Research Institute. Prior to that role, Ms. Boudreau served as CFO for biotech companies Proteostasis Therapeutics and FORMA Therapeutics. Previously, Ms. Boudreau spent 16 years at Novartis and Pfizer, serving in strategy and senior finance roles, including Global CFO, Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. She has contributed to successful product launches, driven sales growth and increased profitability, integrated mergers & acquisitions, and provided leadership across Finance, IT, HR, Strategic Sourcing, Facilities, and Innovation, Quality and Process improvement.

“One of our core priorities at Field Trip is to advance the science and understanding of psychedelic compounds through evidence-based research,” said Ronan Levy, Executive Chairman of Field Trip Psychedelics. “And with the COVID-19 pandemic likely to create one of the greatest mental health challenges the world has ever seen, the need to legitimize the use of these molecules is more urgent than ever. The creation of Field Discovery led by Dr. Bryson, and supported by the many years of operational and executive experience of Dieter and Helen, in conjunction with the technical and scientific knowledge of Mike Ehlers, will help us do just that.”

“The impressive gains in the understanding of brain function, combined with the maturation and development of legitimate research in the field, is demonstrating incredible promise for  therapeutic use of psychedelic molecules like psilocybin and MDMA,” commented Dr. Bryson. “I’m excited to join the Field Trip team. Their commitment to scientific and research excellence in psychedelics, combined with its multidisciplinary structure creates numerous synergies and a dynamic environment, which will greatly advance the understanding and applications of psychedelics and their therapeutic potential. And the need for these advances is more important than ever right now.”

About Field Trip Psychedelics Inc.
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, we help people to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtripdiscovery.com

Posted on

CHAMPIGNON APPOINTS UNIVERSITY OF TORONTO CLINICAL INSTRUCTOR, PHARMACOGNOSIST TO SPECIAL ADVISORY COMMITTEE

VANCOUVER, British Columbia, March 31, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to augment its Special Advisory Committee with the addition of key individuals experienced in highly regulated industries primed for rapid growth. To this accord, the Company is pleased to announce the appointment of Mr. Jay Kheita, ACPR, to its Special Advisory Committee, where he will help lead the integration of Champignon’s novel and natural treatment protocols into its existing consumer packaged goods (“CPGs”) portfolio.

Champignon’s Special Advisory Committee continues to evaluate the potential positive effects of its novel and natural treatment protocols and ongoing pre-clinical trials on individuals suffering from indications such as depression, post traumatic stress disorder (PTSD), traumatic brain injuries (TBI), obsessive compulsive disorder (OCD), as well as substance and alcohol use disorders.

Mr. Khetia holds pharmacy licences in Canada, Australia and England and is a graduate of the University of Brighton, where he achieved an honours degree in pharmacy specializing in pharmacognosy, the study of medicinal plants. Khetia is also a founder of AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator, IP aggregator and solutions provider, and is currently a Clinical Instructor at the Leslie Dan faculty of pharmacy at the University of Toronto.

Khetia strongly believes that alternative health innovations have the potential to treat patients for various chronic diseases, including PTSD, depression and anxiety, thus creating a strong synergy with Champignon’s ongoing psychedelic medicine focused studies and pre-clinical activities.

Gareth Birdsall, CEO of Champignon stated, “We are pleased to welcome Jay to Champignon’s Special Advisory Committee, where he will function as a cornerstone advisor throughout our pursuit to develop and deploy precision medicine focused formulations and delivery systems.”

About Champignon Brands Inc.

Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTC: SHRMF) is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at: https://braxiascientific.com/.

ON BEHALF OF THE BOARD OF DIRECTORS

W. Gareth Birdsall
CEO & Director
E: info@champignonbands.com
T: +1 (778) 549-6714

FOR INVESTOR INQUIRIES:
Tyler Troup
Circadian Group
E: SHRM@braxiascientific.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy Scalabrini, Maricom Inc.
E: rs@maricom.ca
T: (888) 585-MARI

FOR CORPORATE COMMUNICATIONS:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
+1 (212) 418-1217 Office
Editor@NetworkWire.com

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

Posted on

CHAMPIGNON EXPANDS PRECLINICAL PIPELINE WITH MEASURED PSILOCYBIN DOSAGES STUDIES AT UNIVERSITY OF MIAMI

VANCOUVER, British Columbia, March 27, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a health and wellness company specializing in the formulation of medicinal mushrooms health products and novel delivery platforms for the pharmaceutical and nutraceutical industries, has entered into a definitive agreement to acquire Tassili Life Sciences Corp. (“Tassili”), expanding the Company’s preclinical trial pipeline, as well as its aggregation of broad intellectual property (IP) related to the development of novel psychedelics therapeutics and their delivery systems, targeting multiple pathological psychological diseases.

Tassili, in partnership with a multidisciplinary team of scientists and physicians at the University of Miami are working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries (mTBI) and/or post-traumatic stress disorder (PTSD).

TRIALS UNDERWAY

Under a collaborative research agreement with the University of Miami’s Miller School of Medicine (“U of M”), Tassili will conduct preclinical studies and eventual human clinical trials with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD.  Final results are expected in 2021.

Under the terms of the agreement with U of M, Tassili will retain all exclusive rights to inventions, data and IP discovery resulting from the studies which are being led by Dr. Michael Hoffer, professor of otolaryngology and neurological surgery at University of Miami’s Miller School of Medicine.

“Mild traumatic brain injury, especially concussion, is a significant cause of morbidity worldwide,” said Dr. Hoffer. “What many do not realize is that TBI often occurs alongside PTSD. Up to 40% of people impacted by mTBI, a head injury causing a temporary change in mental status or consciousness, or TBI in general, also suffer from PTSD. This combination of mTBI and PTSD is even more common in U.S military members and presents a vast patient population to service and potentially heal with our novel therapeutics under development.”

PSILOCYBIN PATENT PORTFOLIO

Tassili has filed four provisional patents, one of which relates to its ongoing study with the University of Miami. In collaboration with university research institutes, Tassili intends to demonstrate that the clinical and physiological effectiveness in PTSD and obsessive-compulsive disorder (OCD) are enhanced by timely measured dosages of psilocybin and cannabidiol, with superior clinical results as measured by objective outcomes.

Management’s vision is to administer a proven and proprietary combination of psilocybin and CBD in certified drug as well as psychotherapeutic clinics once human clinical trials are completed and the combination is approved by applicable regulatory agencies.

Management also believes that increased specificity to ensure approved, appropriate, standardized and dignified methods of treatment will result from novel delivery systems suiting recovery solutions to specific indications.  Three of the Company’s provisional patents relate to this important part of the drug to patient relationship.

George Scorsis, Chairman of Tassili, stated, “Our development program is championed by the University of Miami, a major U.S. research institution with a worldwide reputation in TBI research and treatment. Working with the University of Miami we aim to shift the mainstream perceptions about psychedelics by establishing the scientific underpinnings of the two compounds’ medical benefits and then developing a prescription-based therapeutic medicine for this combined disorder and a number of other disorders on the horizon, such as obsessive-compulsive disorder (OCD).”

TERMS

Under the terms of the agreement, Champignon will acquire 100% of the issued and outstanding shares of Tassili for total consideration of 16 million common shares in the capital of the Company. A finder’s fee is applicable to this transaction.

About Champignon Brands Inc.

Champignon Brands Inc. (CSE: SHRM) is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at: https://braxiascientific.com/.

ON BEHALF OF THE BOARD OF DIRECTORS

W. Gareth Birdsall
CEO & Director
E: info@champignonbands.com
T: +1 (778) 549-6714

FOR INVESTOR INQUIRIES:
Tyler Troup
Circadian Group
E: SHRM@braxiascientific.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy Scalabrini, Maricom Inc.
E: rs@maricom.ca
T: (888) 585-MARI

FOR CORPORATE COMMUNICATIONS:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
+1 (212) 418-1217 Office
Editor@NetworkWire.com

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

Posted on

CHAMPIGNON BRANDS EXPANDS ALTERNATIVE MEDICINE IP PORTFOLIO WITH KETAMINE, ADAPTOGENIC DELIVERY SYSTEMS/FORMULATIONS

VANCOUVER, British Columbia, March 19, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a health and wellness company specializing in the formulation of a suite of medicinal mushrooms and mushroom-infused products, today introduces new proprietary intellectual property (“IP”) into its vertically integrated alternative medicine product range. The Company is pleased to announce its entry into a definitive agreement, signed March 18, 2020, to acquire Novo Formulations Ltd. (“Novoformulations”).

Novoformulations’ novel delivery system platforms, as well as complementary R&D advancements, will accelerate the architecture of Champignon’s patent portfolio as the Company persists in being a first mover in the existing consumer package goods (“CPGs”) and emerging psychedelic medicine arenas.

Novoformulations is a specialty biotechnology company focused on developing novel and innovative delivery systems for the pharmaceutical and nutraceutical industries. The Novoformulations team consists of a roster of PhDs and technician level scientists, each with decades of experience building novel defensible medical IP, as well as subsequently developing and commercially marketing proprietary delivery platforms.

Novoformulations is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built GMP and pharmaceutical (DIN) licensed facility (the “GMP Formulation Facility”) located in Quebec, Canada, and an accredited pharmacy in Ontario. There, the Company is actively formulating, developing and commercializing bioavailable delivery platforms, including:

  • Transdermal (topical);
  • Intranasal;
  • Sublingual; and,
  • Novel oral and suppository.

Also based in Quebec, Novoformulations’ manufacturing partner will process its novel delivery platforms and formulations into marketable end products at its 40,000-square-foot GMP-certified, Health Canada and Federal Drug Administration (FDA)-approved manufacturing facility.

Champignon plans to leverage Novoformulations’ existing product development infrastructure and licensed affiliates to pursue psilocybin and MDMA based formulations, with the objective of developing and commercializing rapid onset treatments capable of improving health outcomes, including Depression, PTSD and substance and alcohol use disorders (DPS). The current marketplace for pharmacologic DPS treatments in North America exceeds $10 billion annually.[1]

“The recent acquisitions of Novoformulations and Artisan Growers are absolutely accretive to each other and to our stated business objectives of enhancing the health and wellbeing of millions of consumers via our suite of medicinal mushroom extracts, mushroom-infused products and now novel delivery systems,” Champignon Chief Executive Officer Gareth Birdsall commented.

“The existing infrastructure inherited from these recent acquisitions positions us as a leading participant throughout the entire alternative medicine lifecycle, from R&D to formulation, manufacturing and end distribution. The end result will be a turnkey solution that incorporates both standardized ingredient mixtures and pharmaceutical grade products that can now be marketed via a variety of proprietary delivery systems,” continued Gareth Birdsall. “The addition of Novoformulations allows Champignon to deliver medications in a safer, more effective and more expeditious manner than our peers, from bench top in the laboratory, to preclinical and clinical trials. We are intent on the commercialization of products throughout North America, as rapidly as is safely and effectively practicable.”

The Novoformulations’ team works alongside multiple first-class university institutions, as well as collaborates with medical professionals and associated clinics in numerous Health and Wellness spaces that include: Psychiatry (depression, anxiety, PTSD, OCD); Addiction (alcohol drug, obesity); Neurology (concussion and neuropathic pain); Rheumatology (osteoarthritis, rheumatoid arthritis); Aging (dementia, probable Alzheimer’s, mini-strokes); and metabolic disorders (diabetes).

Champignon will also look to integrate its existing medicinal mushroom extracts, as well as fungi cultivated at its Artisan Growers’ facility, into certain proprietary delivery systems developed by Novoformulations. The Company has successfully formulated a functional mushroom blend, which includes but is not limited to the following fungi varietals:

  1. Reishi: an adaptogen with anti-inflammatory, cholesterol-lowering and known anti-viral properties;
  2. Lion’s Mane: a mushroom with adaptogenic-like properties for improved cognitive functions; and,
  3. Chaga: a mushroom with adaptogenic-like properties, which may act as a neuroprotective agent and may boast anti-viral and anti-cancer properties.

Under the terms of the Agreement, Champignon will acquire 100 percent of the issued and outstanding shares of Novoformulations for total consideration of 12.5 million common shares in the capital of the Company at a deemed price of $0.2475 per share. A finder’s fee is applicable to this transaction.

[1] Source: https://www.prnewswire.com/news-releases/antidepressant-drugs-market-to-reach-15-98-bn-by- 2023-globally-at-2-1-cagr-says-allied-market-research-873540700.html

 

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is intent on being a global, vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom formulations. For more information, visit the company’s website at www.ChampignonBrands.com.

ON BEHALF OF THE BOARD OF DIRECTORS

W. Gareth Birdsall
CEO & Director
E: info@champignonbands.com
T: +1 (778) 549-6714

FOR INVESTOR INQUIRIES:
Tyler Troup
Circadian Group
E: SHRM@braxiascientific.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy Scalabrini, Maricom Inc.
E: rs@maricom.ca
T: (888) 585-MARI

FOR CORPORATE COMMUNICATIONS:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
+1 (212) 418-1217 Office
Editor@NetworkWire.com

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

Posted on

CHAMPIGNON BRANDS TO ACQUIRE CRAFT MUSHROOM CULTIVATOR

VANCOUVER, British Columbia / March 13, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496), a wellness company specializing in medicinal mushroom and mushroom-infused products, continues to accelerate its vertical integration through the addition of craft mushroom production, manufacturing and research capabilities. The Company is pleased to announce it has entered into a definitive agreement (the “Agreement”) to acquire Artisan Growers Ltd. (“Artisan Growers”), a British Columbia based craft mushroom cultivator and supplier.

Artisan Growers operates a craft mushroom cultivation facility capable of producing an assortment of organic craft mushroom varietals including Lion’s Mane, Chaga, Reishi and Agaricus Blazei. Artisan Growers utilizes a variety of cultivation techniques and grow infrastructure to produce premium craft mushrooms.

Champignon plans to integrate Artisan Growers’ craft mushroom production capacity into its existing medicinal mushroom manufacturing, formulation and distribution infrastructure as the Company continues to control its supply chain directly to the end user.

Champignon has apportioned and allocated a dedicated laboratory area (the “Laboratory Area“) within the existing Artisan Growers facility for specific research and development (“R&D”) activities and fungi profile analysis, with the objective of:

  • Further investigating the integration of its mushroom extracts as an alternative medicine delivery system;
  • Formulating bioactive compounds extracted from plants/fungi;
  • Cultivating fungi varietals, which will include psilocybin, to be commenced as soon as the Company has determined the appropriate regulatory approvals have been received; and,
  • Isolating and synthesizing of certain plant/fungi extracts.

“With the acquisition of Artisan Growers, we continue to optimize our upstream, downstream and distribution capabilities, all the while securing valuable infrastructure to expedite our R&D pursuits,” stated Gareth Birdsall, Chief Executive Officer of Champignon Brands. “Over the coming quarters we will tactically execute on our stated business plan and look to also emerge as a best-in-class vertically integrated medicinal mushroom extract formulator, integrating alternative medicine, clinical research and vocational rehabilitation into the Company’s current product portfolio.”

Under the terms of the Agreement, Champignon will acquire 100 percent of the issued and outstanding shares of Artisan Growers for total consideration of 8 million common shares in the capital of the Company (the “Consideration Shares”). The Consideration Shares will be issued at an attributed price equal to a five-day volume-weighted average price at the time of issuance. A finder’s fee is applicable to this transaction.

About Champignon Brands Inc.

Champignon Brands has positioned itself to rapidly become a global force as a vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom and mushroom-infused formulations.

ON BEHALF OF THE BOARD OF DIRECTORS

W. Gareth Birdsall
CEO & Director
E: info@champignonbands.com
T: +1 (778) 549-6714

FOR INVESTOR INQUIRIES:
Tyler Troup
Circadian Group
E: SHRM@braxiascientific.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:

Remy Scalabrini, Maricom Inc.
E: rs@maricom.ca
T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

Posted on

Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations

NEWS PROVIDED BY
Mind Medicine (MindMed) Inc.

Mar 12, 2020, 06:00 ET

‍

Mind Medicine (MindMed) Inc. (“MindMed”) has formed a Technology Evaluation, Acquisition and Scientific Integrity Board Committee to identify and expand the company’s clinical trial pipeline and IP portfolio of psychedelics. The committee will be advised by Johns Hopkins Professor of Psychiatry and Behavioral Sciences Matthew Johnson, Ph.D.  Professor Johnson is a renowned expert on psychedelics and addiction. He will act as both a senior advisor to the newly formed committee and will also join the company’s existing Scientific Advisory Board. In addition, pharma industry veteran and skilled psychiatry clinician Dr. Miri Halperin Wernli, who recently joined the board of directors and will be the chair of the board committee, will also act as senior advisor for MindMed’s clinical trials.

“We feel it is important to establish a world class team of experts to advise on the scientific merit and medical capabilities of our future acquisitions and pipeline,” said MindMed Founder and Co-CEO JR Rahn. “Professor Johnson and Dr. Halperin Wernli will be integral advisors to us as we evaluate new opportunities and build the most compelling clinical trial pipeline for psychedelics.”

Professor Matthew Johnson added: “MindMed is poised to make important advances in mental health treatment by developing psychedelic-based medicines. MindMed understands that meaningful and sustainable advances will be made when academics partner with industry to safely and responsibly shepherd these medicines through the approved medical regulatory process.”

With society facing huge challenges with anxiety, suicide and addictions, MindMed is aiming to use psychedelics to treat various mental disorders and provide an opportunity to discover the basic neuroscience of how these drugs really affect brain activity. MindMed aims to develop medicines derived from psychedelics to address significant unmet medical needs.

Dr. Miri Halperin Wernli said: “Psychiatry is in desperate need of fundamental mechanistic advances and MindMed is in the best position to bring the change needed. MindMed is well positioned to develop, scale, and deploy psychedelic-based medicines for the treatment of intractable mental health disorders. Their focus on, and partnerships with, academia is a key to this solid foundation and potential.”

The Technology Evaluation, Acquisition and Scientific Integrity Board Committee is expected to be composed of the following MindMed board members: Executive Chairman & Co-CEO Stephen Hurst, Board Director & Senior Advisor Miri Halperin Wernli, and Director & Co-CEO JR Rahn.

###

About Professor Matthew Johnson, Ph.D.

Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, is an expert on psychedelics, other drugs, and addiction. Working with psychedelics for 16 years, he has published approximately 50 scientific papers on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended Schedule IV upon medical approval. He has guided >100 psychedelic sessions. Matt also conducts behavioral economic research on both addiction and sexual risk. He conducts research with most psychoactive drug classes, was 2018 President of the Psychopharmacology Division of the American Psychological Association, and is current President of the International Society for Research on Psychedelics. Interviewed by: 60 Minutes (CBS News), New York Times, Washington Post, Wall Street Journal, BBC, CNN, Fox Business News, NPR, and Michael Pollan.

About Dr. Miri Halperin Wernli

Dr. Halperin Wernli is a senior pharmaceutical and biomedical executive with over 30 years of strategic and operational leadership in the biopharmaceutical industry.  Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Dr. Halperin Wernli is a skilled clinician in child and adult psychiatry and an experienced Pharmaceutical leader with skills and broad expertise in Drug Development, Regulatory Affairs, Project & Portfolio Management, Development Finance & Controlling, and Corporate Strategy and Governance. Dr. Halperin Wernli currently serves as CEO of Creso Pharma, a listed cannabis company focused on the development and commercialization of cannabis and hemp derived therapeutic and nutraceutical products for human and animal health.

About MindMed

Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for Adult ADHD. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines.

For more information: www.mindmed.co.

MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:BGHM.

Posted on

Field Trip Psychedelics Inc. Opens First of its Kind Psychedelic-Enhanced Psychotherapy Clinic in Toronto

TORONTO, March 4, 2020 /PRNewswire/ — Field Trip Health Inc., a wholly owned subsidiary of Field Trip Psychedelics Inc., (“Field Trip” or the “Company“), the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, today announced the opening of its first medical centre, in Toronto, dedicated exclusively to the administration of psychedelic-enhanced psychotherapy.

The clinic was founded in response to the urgent need to combat the spiraling mental health crisis facing Canada and the world, which is a result of the limited effectiveness of current pharmacologic treatments like antidepressants. The first psychedelic that will be administered to patients, in conjunction with Field Trip’s custom developed psychotherapy protocol, is ketamine. Evidence shows that ketamine, which is a dissociative psychedelic, is safe and can provide almost immediate and enduring relief from depression symptoms. Beyond its antidepressant effects, ketamine’s  ability to promote neuroplasticity makes it a powerful tool to pair with Field Trip’s comprehensive psychotherapy program.

“Multiple evidence-based studies from world-class institutions like New York University and Johns Hopkins have demonstrated that using psychedelics and psychedelic-enhanced psychotherapy can have profound, sustained results in as little as one session in addition to having positive side effects such as improved well-being, optimism and increased neural plasticity,” said Dr. Michael Verbora, Field Trip Health’s Canadian Medical Director. “Ketamine has been identified by the former Director of the National Institute of Mental Health as one of the most important breakthroughs in antidepressant treatment in decades. As new molecules or classic psychedelics like psilocybin, LSD and MDMA get approved or legalized, we will begin to incorporate them into the practice as well.”

The Toronto centre was custom designed to offer a welcoming, world-class experience to demonstrate first-hand how psychedelics can profoundly transform the lives of patients and current approaches to mental health and wellness treatment.

“Set and setting play an instrumental role in maximizing the therapeutic experience of psychedelic-enhanced psychotherapy,” adds Ronan Levy, Executive Chairman of Field Trip. “For that reason, we have invested heavily in designing a centre that is bright and welcoming. Not only is our Toronto location an inviting space for psychedelic-enhanced psychotherapy, we believe it is one of the most beautiful medical clinics in Canada.”

Psychiatrists at the clinic have begun conducting initial consultations and the first patients to experience a ketamine experience will be seen shortly.

The clinic is located at 30 Duncan St., Suite 400, Toronto, ON, M5V 2C3, Canada and patients can book a consultation by phone (1-833-222-0084), email (hi@fieldtriphealth.com) or online at https://fieldtriphealth.com/#contact

About Field Trip Psychedelics Inc.
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com

Posted on

End-to-end solution in psychedelic therapies establishes Numinus as leader in emerging space

VANCOUVER (February 24, 2020)—With momentum building for the use of psychedelic substances in the treatment of mental illness, addiction and trauma, Vancouver-based Numinus Wellness Inc. (“Numinus”) is now one of the first in-market, fully integrated companies in the psychedelic space in North America.

Numinus is an operating company at the forefront of the transformative change in treating the growing prevalence of mental health issues and desire for greater wellness. The company was created from the merger of Salvation Botanicals and Numinus Wellness Inc. and aims to go public via an RTO with Rojo Resources in Q1 2020, subject to exchange approval. Psychedelic therapies have been designated breakthrough therapy status by the FDA due to their promising therapeutic potential.

“While we are excited about the future of psychedelics, these substances will not be approved for recreational use; this is not cannabis,” says Numinus CEO and Founder Payton Nyquvest. “Psychedelics are therapeutic, where the application of these substances will only happen in safe, controlled treatment environments.”

Through Salvation Labs (a Numinus subsidiary), Numinus has a dealer’s licence which allows Numinus to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Numinus is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through the supply and distribution of these substances.

Numinus is currently operating a stand-alone centre offering patients integrative health solutions to help heal, connect and grow. A purpose-built facility is planned for Vancouver in 2020.

The company’s goal is to create and operate a network of wellness centres offering a unique set of treatments that can be specifically developed for each individual. In future and when approved for use by appropriate regulatory bodies, Numinus aims to guide suitable candidates in the use of psychedelics. Numinus would conduct these therapies working in partnership with various health and research organizations.

Numinus is led by Payton Nyquvest and Stacey Wallin, proven entrepreneurs and business leaders who have benefitted from transformative therapies in their own lives. The pair has built a strong network of executives, advisors and partners to take Numinus to the market.

“The societal costs of mental illness, addictions, trauma and unmet human potential are much too high,” Nyquvest says. “New approaches, new treatments and new ways of thinking are required — solutions where the world of health care and technology collide — to help individuals and communities heal, discover meaning and make deeper connections.”

Contact:

Emily Edwards | NATIONAL Vancouver

Email: eedwards@national.ca | Phone: 604-842-6490

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Posted on

Field Trip Psychedelics Inc. Announces Closing of Oversubscribed Series A Financing

TORONTO, Feb. 6, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, is pleased to announce the closing of its oversubscribed Series A financing round. The financing, which was completed through a private placement, raised $8.5M USD for the Company.

The funds will be used to execute the initial stages of Field Trip’s strategic plan to build out the world’s first network of medical centres focused exclusively on psychedelic-enhanced psychotherapy. Additionally, the financing will help fund the final construction of its research and cultivation facility at the University of the West Indies in Jamaica that is dedicated to the study of psilocybin-producing mushrooms and the discovery of novel therapeutic molecules.

“The interest we had in this financing came from a broad and varied group of academics, entrepreneurs, medical professionals, financial professionals and investment funds,” said Ronan Levy, Executive Chairman of Field Trip. “The ability to pull together such a thoughtful, supportive and diversified investor base is certainly a tribute to the team at Field Trip and the work we are doing. It also speaks profoundly to the level of interest, excitement and importance that people around the world are placing on the advancement of psychedelics and the role they may play in improving mental health, performance, general wellness and happiness.”

The financing was led by Field Trip’s founders and Singhal Health Foundation. Other notable investors in the round include Subversive Capital, Silver Spike Capital and the venture capital firm Bolt, as well as individual investors Harris Fricker, an early stage investor and pioneer in e-payments and blockchain, and Ben Greenfield, a globally recognized longevity expert and biohacker.

Triple Bottom Line: People, Planet and Profit

Additionally, Field Trip has amended its Articles of Incorporation to reflect its commitment to Triple Bottom Line operations. A “Triple Bottom Line” approach to business (commonly described as “people, planet and profit”) requires an organization to assess and account for its social and environmental impacts, in addition to its financial impacts in its decision-making processes.

Sanjay Singhal, Founder of the Singhal Health Foundation, said, “Nearly 1 in 4 people will be diagnosed with a mental health condition in their lifetime. By 2023, depressive disorders will be the single largest cause of the burden of disease globally. Addressing the global mental health crisis requires effort, work and coordination from people and organizations of all forms; academic, non-profit and for-profit. The team at Field Trip blends the right balance of a track record of success, ambition, and commitment to ethical and thoughtful business practices, which is why I’m excited to support their efforts and work closely with them to achieve their mission.”

About Field Trip Psychedelics Inc.
Field Trip is world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com

Posted on

A Patented Psilocybin Nasal Spray Is Coming. Will Legalization Be Fair?

On December 4, Oregon-based startup company Silo Wellness announced that it has developed a “patent-pending nasal spray for microdosing psilocybin.” The aerosol spray would deliver into each nostril a precise dose of vaporized psilocybin that the company calls “sub-psychedelic.”

Silo Wellness, a company headquartered in Oregon, is developing the drug in Jamaica, where psilocybin mushrooms are legal. The company claims the nasal spray is safer, more predictable and more palatable than simply eating mushrooms. It plans to market the drug if or when states like Oregon legalize psilocybin.

“With proof of concept in hand, we are taking pre-orders and entertaining licensing proposals for research abroad and manufacturing for the product in advance of jurisdictions coming online legally, similar to Oregon’s proposed medical-marijuana-like psilocybin initiative,” said COO Scott Slay in a press release. “We are so grateful for the opportunity to have an actual and real first-to-market consumer product in magic mushrooms. Most of us were too early to cannabusiness or too late.”

Currently, no city or state in the US allows legal sales of psilocybin products. But as Filter has reported, Denver, Colorado and Oakland, California each decriminalized personal use, possession and cultivation of psilocybin mushrooms this year. The new laws explicitly prohibit buying or selling. About 100 other cities across the country are, with varying success, trying to replicate these reforms.

There’s also a statewide effort in California. While decriminalization is the term being used by the ballot campaign, organizers are actually proposing a framework to legalize and regulate mushroom sales in a manner similar to cannabis.

In Oregon, advocates are now gathering signatures for a “Psilocybin Service Initiative.” Under this proposed reform, the state would legalize manufacture, delivery and administration of psilocybin mushrooms at licensed therapeutic clinics. Medical professionals would be able to facilitate psilocybin sessions for patients who might benefit. The organizers removed decriminalization language from their proposal in September.

So it is likely that in the mid-term, some US states will legalize psilocybin and enrich early-to-market companies like Silo Wellness. But as firms seek profits, activists should be vigilant to ensure that the benefits of legalization are shared equitably.

This is no more instructive example of this imperative than the problematic rollout of cannabis legalization.

While states like Illinois have rushed to open the doors of dispensaries, they have simultaneously neglected hundreds of thousands of residents with life-constraining cannabis convictions who are now eligible for expungement. It remains time-consuming, complicated and expensive to expunge a conviction—if you even know you’re eligible.

And then there is the highly segregated executive leadership of the cannabis industry, with people from the communities of color most impacted by prohibition and policing widely excluded.

While the number of people with psilocybin convictions is likely just a fraction of those with cannabis convictions, states should still prioritize expungement and other forms of post-conviction relief. The hypocrisy of allowing employers, banks or police to legally discriminate against people with a drug arrest or conviction, while start-ups generate millions selling the same drug, should not be repeated.

In Oregon, another ballot initiative, called the 2020 Drug Addiction Treatment and Recovery Act, is also gathering signatures. This one would decriminalize low-level possession of most controlled substances, including psilocybin.

Criminal offenses would be reduced to civil offenses, subject to a $100 fine or mandatory “health assessments.” But Oregonians, then, would still face a situation where they cannot legally access drugs like psilocybin outside of a licensed facility or without purchasing from brands like Silo Wellness. Silo would presumably sell their product in Oregon only to licensed psilocybin providers. 

The company claims that it wants its drug to be widely accessible. “After [his first psilocybin experience] very late in life, then-41-year-old [CEO Mike Arnold], couldn’t stop thinking about how to bring this to the masses as quickly and inexpensively as possible,” the press release states.

“Mushrooms and DMT saved me,” Slay added. “My life was renewed. I now have peace and purpose, and I can’t wait to share this opportunity with the world.”

But advocates will need to scrutinize how “inexpensive” the product will be. The company is seeking a patent for its psilocybin vaporizing technology, as well as for other psychedelic substances like ayahuasca, DMT, peyote and mescaline. This raises some natural questions.

Silo Wellness did not respond to Filter‘s request for comment by publication time.